Boston Scientific Corporation Announces Preliminary Unaudited Sales for the Fourth Quarter and Full Year 2019; Updates Earnings Guidance for the Fourth Quarter and Full Year of 2019
For the year, the company reported net sales of $10.74 billion against $9.82 billion a year ago.
The company estimates that it will exceed its previously issued guidance for earnings of $0.22 to $0.25 for the fourth quarter and $0.72 to $0.75 per share for the full year 2019, on a GAAP per share basis, primarily due to a significant non-cash tax benefit arising from an intra-entity asset transfer of intellectual property completed in the fourth quarter of 2019.